BR112022017852A2 - Vacinas para herpes zoster compreendendo um agonista de tlr9 - Google Patents

Vacinas para herpes zoster compreendendo um agonista de tlr9

Info

Publication number
BR112022017852A2
BR112022017852A2 BR112022017852A BR112022017852A BR112022017852A2 BR 112022017852 A2 BR112022017852 A2 BR 112022017852A2 BR 112022017852 A BR112022017852 A BR 112022017852A BR 112022017852 A BR112022017852 A BR 112022017852A BR 112022017852 A2 BR112022017852 A2 BR 112022017852A2
Authority
BR
Brazil
Prior art keywords
herpes zoster
tlr9 agonist
vaccines
tlr9
agonist
Prior art date
Application number
BR112022017852A
Other languages
English (en)
Inventor
d campbell John
N Hyer Randall
S Janssen Robert
Novack David
Original Assignee
Dynavax Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynavax Tech Corp filed Critical Dynavax Tech Corp
Publication of BR112022017852A2 publication Critical patent/BR112022017852A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3183—Diol linkers, e.g. glycols or propanediols
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/336—Modified G
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16771—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

VACINAS PARA HERPES ZOSTER COMPREENDENDO UM AGONISTA DE TLR9. A presente invenção refere-se a composições imunogênicas compreendendo um antígeno de glicoproteína E do vírus varicela zoster (VZV) e um agonista do receptor 9 do tipo toll (TLR9), tal como um oligonucleotídeo compreendendo um motivo de citidina-fosfo-guanosina (CpG) não metilado. As composições imunogênicas são adequadas para estimular uma resposta imune contra VZV em um indivíduo em necessidade das mesmas.
BR112022017852A 2020-03-09 2021-03-09 Vacinas para herpes zoster compreendendo um agonista de tlr9 BR112022017852A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062987243P 2020-03-09 2020-03-09
PCT/US2021/021544 WO2021183540A1 (en) 2020-03-09 2021-03-09 Shingles vaccines comprising a tlr9 agonist

Publications (1)

Publication Number Publication Date
BR112022017852A2 true BR112022017852A2 (pt) 2022-11-01

Family

ID=77672121

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022017852A BR112022017852A2 (pt) 2020-03-09 2021-03-09 Vacinas para herpes zoster compreendendo um agonista de tlr9

Country Status (11)

Country Link
US (1) US20230061403A1 (pt)
EP (1) EP4117726A4 (pt)
JP (1) JP2023517597A (pt)
KR (1) KR20230013237A (pt)
CN (1) CN115768892A (pt)
AU (1) AU2021236059A1 (pt)
BR (1) BR112022017852A2 (pt)
CA (1) CA3174927A1 (pt)
IL (1) IL296283A (pt)
MX (1) MX2022011159A (pt)
WO (1) WO2021183540A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3241245A1 (en) * 2021-12-23 2023-06-29 Robert S. Janssen Immunogenicity of a cpg-adjuvanted herpes zoster vaccine
CN118085111A (zh) * 2024-04-28 2024-05-28 天津中逸安健生物科技有限公司 一种融合蛋白gE-Fc及其在制备重组带状疱疹疫苗中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0109297D0 (en) * 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
EP2901856B1 (en) * 2004-06-15 2017-08-09 Idera Pharmaceuticals, Inc. Immunostimulatory oligonucleotide multimers
WO2007120368A2 (en) * 2006-01-09 2007-10-25 The Regents Of The University Of California Immunostimulatory combinations for vaccine adjuvants
CN102517302A (zh) * 2011-12-28 2012-06-27 中国人民解放军军事医学科学院野战输血研究所 一种重组表达水痘-带状疱疹病毒截短型糖蛋白e的方法及其应用
EP3041505A4 (en) * 2013-09-05 2017-04-19 Merck Sharp & Dohme Corp. Methods of immunization with varicella zoster virus antigen
EP3079717A1 (en) * 2013-12-09 2016-10-19 Bullet Biotechnology, Inc. Specific virus-like particle-cpg oligonucleotide vaccines and uses thereof
US20190298824A1 (en) * 2016-05-04 2019-10-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Albumin-binding immunomodulatory compositions and methods of use thereof
EP3560512A4 (en) * 2016-12-26 2020-07-22 Mogam Institute for Biomedical Research COMPOSITION OF VACCINE AGAINST ZONA
CN109602901B (zh) * 2019-01-08 2022-05-27 成都迈科康生物科技有限公司 一种带状疱疹病毒疫苗及其制备方法和应用

Also Published As

Publication number Publication date
AU2021236059A1 (en) 2022-11-03
KR20230013237A (ko) 2023-01-26
JP2023517597A (ja) 2023-04-26
IL296283A (en) 2022-11-01
CA3174927A1 (en) 2021-09-16
CN115768892A (zh) 2023-03-07
EP4117726A4 (en) 2024-03-27
EP4117726A1 (en) 2023-01-18
WO2021183540A1 (en) 2021-09-16
US20230061403A1 (en) 2023-03-02
MX2022011159A (es) 2022-11-14

Similar Documents

Publication Publication Date Title
BR112022017852A2 (pt) Vacinas para herpes zoster compreendendo um agonista de tlr9
PE20152002A1 (es) Composiciones y metodos para modular la expresion de ttr y vhb
ES2749627T3 (es) Complejo que contiene oligonucleótido que tiene actividad inmunoestimulante y su uso
ES2562456T3 (es) Uso de un adyuvante que induce una respuesta inmune Th1 para mejorar las respuestas inmunes
BR112018008090A2 (pt) vacina de vírus do herpes simplex.
UY31280A1 (es) Oligonucleotidos inmunoestimuladores con un motivo de combinacion con actividad mejorada
BRPI0410702A (pt) polinucleotìdeo isolado, composição, métodos para preparar um vìrus de influenza e um veìculo de liberação de genes, e para imunizar um indivìduo contra um patógeno, vìrus, célula, e, vetor
BR112018017307A2 (pt) molécula de ácido nucleico isolada, composição, e, métodos para indução de uma resposta imune contra um zika vírus, para tratamento de um indivíduo e para prevenção de uma infecção por zika vírus
UY38015A (es) Composiciones inmunoestimulantes
MX2019007288A (es) Composicion de vacuna para herpes zoster.
BR112022016992A2 (pt) Vacina com base em poxvírus recombinante contra ví-rus sars-cov-2
CL2021003211A1 (es) Una cepa viva modificada, del virus del síndrome respiratorio y reproductivo porcino (prrs), vacuna que lo comprende y su uso para tratar el prrs tipo ii. (divisional solicitud no. 2123-2018)
Sandgren et al. Understanding natural herpes simplex virus immunity to inform next‐generation vaccine design
AR103427A1 (es) Vacuna contra la fiebre aftosa
BR112014023414A2 (pt) vacina de herpesvirus-1 equino recombinante contendo uma glicoproteína c mutante e seus usos
MX2022010642A (es) Vacunas contra coronavirus que comprenden un agonista de tlr9.
CL2023001826A1 (es) Eliminación genómica en la vacuna contra la peste porcina africana que permite un crecimiento eficaz en estirpes celulares estables
CL2022002456A1 (es) Inmunización activa contra el tétanos, la difteria y la tos ferina.
BR112021025286A2 (pt) Vacina contra o hiv com base em células t alogênicas para induzir a imunidade celular e humoral
ZA202104747B (en) Novel trypanosomal vaccine
UY32876A (es) Régimen de inmunización por sensibilización-refuerzo heteróloga
AR105539A1 (es) Potenciamiento de la respuesta inmunológica en especies acuáticas
AR113950A1 (es) Composiciones inmunoestimulantes
BR112018070126A8 (pt) composição imunogênica, e, métodos para induzir uma resposta imune a um antígeno e uma proteção imune inata.
AR113949A1 (es) Oligonucleótidos inmunoestimulantes